Abstract
Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Current Cancer Therapy Reviews
Title:BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Volume: 8 Issue: 2
Author(s): P. Daisy and K. Saipriya
Affiliation:
Keywords: Apoptosis, Bcl-2 family, BH-3 Domain, Molecular pathways, Small molecule inhibitors
Abstract: Apoptosis is an induced and ordered process in which the cell actively participates in bringing about its own death. Dysregulation in either of the apoptotic pathways leads to various diseases including cancer, neurodegenerative disorders and autoimmunity. Bcl-2 (B cell lymphoma 2) proteins such as pro-and anti-apoptotic play a vital role in the mitochondrial pathway of apoptosis which results in cellular commitment to death or cell survival. So, therefore many small molecule antagonists that targets Bcl-2 anti-apoptotic proteins that lead to cellular survival are in their pre-clinical and clinical stages. In this review we focus on the apoptotic players of Bcl-2 group of proteins and their anti-apoptotic inhibitors.
Export Options
About this article
Cite this article as:
Daisy P. and Saipriya K., BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators, Current Cancer Therapy Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157339412800675414
DOI https://dx.doi.org/10.2174/157339412800675414 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycyrrhizic Acid Derivatives as New Antiviral and Immune Modulating Agents
Current Bioactive Compounds Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery A Systematic Review of the Molecular Mechanisms of Uranium -Induced Reproductive Toxicity
Inflammation & Allergy - Drug Targets (Discontinued) Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology GVHD: Complication and Challenge to Successful Allogeneic Hematopoietic Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
Current Cancer Drug Targets The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry